Curexo Inc. (060280.KQ)

KRW 9030.0

(1.46%)

EBITDA Summary of Curexo Inc.

Curexo Inc.'s latest annual EBITDA in 2023 was -2.75 Billion KRW , up 16.67% from previous year.
Curexo Inc.'s latest quarterly EBITDA in 2024 Q2 was -753.39 Million KRW , down -475.63% from previous quarter.
Curexo Inc. reported an annual EBITDA of -236.41 Million KRW in 2022, up 320.07% from previous year.
Curexo Inc. reported an annual EBITDA of -567.19 Million KRW in 2021, down -201.22% from previous year.
Curexo Inc. reported a quarterly EBITDA of -753.39 Million KRW for 2024 Q2, down -475.63% from previous quarter.
Curexo Inc. reported a quarterly EBITDA of 1.57 Billion KRW for 2023 Q1, up 59.96% from previous quarter.

Annual EBITDA Chart of Curexo Inc. (2023 - 2016)

Historical Annual EBITDA of Curexo Inc. (2023 - 2016)

Year	EBITDA	EBITDA Growth
2023	-2.75 Billion KRW	16.67%
2022	-236.41 Million KRW	320.07%
2021	-567.19 Million KRW	-201.22%
2020	1.08 Billion KRW	128.78%
2019	-3.64 Billion KRW	13.9%
2018	-28.86 Billion KRW	-589.66%
2017	-16.48 Billion KRW	102.31%
2016	4.43 Billion KRW	0.0%

Year	EBITDA	EBITDA Growth
2024 Q1	-1.15 Billion KRW	102.85%
2024 Q2	-753.39 Million KRW	-475.63%
2023 Q1	1.57 Billion KRW	59.96%
2023 Q2	1.37 Billion KRW	-12.33%
2023 Q3	52.09 Million KRW	-96.22%
2023 Q4	-273.35 Million KRW	-624.72%
2023 FY	- KRW	16.67%
2022 Q2	-148.94 Million KRW	-136.96%
2022 FY	- KRW	320.07%
2022 Q4	982.28 Million KRW	-10.82%
2022 Q3	1.1 Billion KRW	839.49%
2022 Q1	402.99 Million KRW	-24.71%
2021 FY	- KRW	-201.22%
2021 Q4	535.24 Million KRW	189.13%
2021 Q3	-600.49 Million KRW	0.0%
2020 FY	- KRW	128.78%
2019 FY	- KRW	13.9%
2018 FY	- KRW	-589.66%
2017 FY	- KRW	102.31%
2016 FY	- KRW	0.0%

Peer EBITDA Comparison of Curexo Inc.

Name	EBITDA	EBITDA Difference
Osang Healthcare Co.,Ltd	157.89 Billion KRW	101.744%
InBody Co.,Ltd	44.25 Billion KRW	106.222%
Seegene, Inc.	35.65 Billion KRW	107.723%
i-SENS, Inc.	24.14 Billion KRW	111.405%
Ray Co., Ltd.	7.62 Billion KRW	136.117%
Gencurix Inc.	-18.09 Billion KRW	84.78%
Sugentech Inc.	-12.13 Billion KRW	77.302%
L&C Bio Co., Ltd	13.4 Billion KRW	120.546%